UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000034280
Receipt number R000039074
Scientific Title Elucidation of the mechanism of oral tolerance induction to the transgenic rice containing peptides from Japanese cedar pollen allergens and the efficacy of long-term administration.
Date of disclosure of the study information 2018/09/26
Last modified on 2019/04/23 13:17:27

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Elucidation of the mechanism of oral tolerance induction to the transgenic rice containing peptides from Japanese cedar pollen allergens and the efficacy of long-term administration.

Acronym

Elucidation of the mechanism of oral tolerance induction to the transgenic rice containing peptides from Japanese cedar pollen allergens and the efficacy of long-term administration.

Scientific Title

Elucidation of the mechanism of oral tolerance induction to the transgenic rice containing peptides from Japanese cedar pollen allergens and the efficacy of long-term administration.

Scientific Title:Acronym

Elucidation of the mechanism of oral tolerance induction to the transgenic rice containing peptides from Japanese cedar pollen allergens and the efficacy of long-term administration.

Region

Japan


Condition

Condition

Japanese cedar pollinosis

Classification by specialty

Oto-rhino-laryngology

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

Long-term administration of the transgenic rice containing peptides from Japanese cedar pollen allergens and elucidation of the mechanism of oral tolerance induction.

Basic objectives2

Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

Subjective symptoms
-Scoring of allergy diaries between placebo group and transgenic rice group are compared

Key secondary outcomes

1.Surveys on lifestyles
2.JRQLQ
3.Intranasal observation with rhinoscopy
4.Intradermal reaction, number of nasal eosinophil, total serum IgE and cedar pollen-specific IgE
5.Immunological test:Evaluation of T-cell responses to 7crp, Cry j 1 and cry j 2.
6.Examination of height, weight, BMI,body temperature,blood pressure and pulse count
7.Safety (adverse events)


Base

Study type

Interventional


Study design

Basic design

Parallel

Randomization

Randomized

Randomization unit

Individual

Blinding

Double blind -all involved are blinded

Control

Placebo

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

3

Purpose of intervention

Prevention

Type of intervention

Food

Interventions/Control_1

Evaluation of the efficacy of oral administration group of 20g of transgenic rice for 24 weeks

Interventions/Control_2

Evaluation of the efficacy of oral administration group of 5g of transgenic rice for 24 weeks

Interventions/Control_3

Evaluation of the efficacy of oral administration group of 50g of placebo rice for 24 weeks

Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit

70 years-old >

Gender

Male and Female

Key inclusion criteria

1) Adult aged over 20years old and under 70years old and lives or works near The Jikei University School of Medicine.
2) A person who has allergic symptoms such as sneezing, running nose, and nasal obstruction.
3) A person who gives a positive result in provocative test and intradermal test (please refer to appendix for an assessment procedures)
4) Cedar pollen allergen-specific IgE antibody values over Class II.
5) Cypress specific IgE antibody values under Class IV.
6) Stimulation index of T-cell response to allergens over 2.0.

Key exclusion criteria

1) A person who is allergic to Rice or has a history of Rice allergy.
2) A person who shows House dust specific IgE antibody valued over Class V, and has chronic rhinitis
3) A person who is imperative to use medicine such as anti-allergic agent and steroidal chemicals that potentially influence the outcome of evaluation.
4) A person who underwent an operation that is accompanied to nasal disorder within last 2years, or has nasal disorder such as acute/chronic-rhinitis, rhinopolypus, hypertronic rhinitis, septal deviation, sinusitis which all are potentially hinder to the outcome of evaluation.
5) A person who has any disorders under treatment and the condition is unstable that trial investigator has asessed as mismatched participant.
6) A person who has a history of serious disorder such as diabetes, hepatic disorder, kidney disorder, and cardiac disorder.
7) A person who takes beta-blocker in order to treat complecating disorders such as hypertension, and / or cardiac disorder.
8) A person who takes alpha-blocker in order to treat complecating disorders such as prostatic hyperplasia.
9) A person who is complecated by immunodeficiency disorder, cancer, or severe enemia.
10) A person who is complecated by asthma.
11) A person who has laboratory abnormalities in the pre-clinical test that trial investigator has assessed as mismatched participant.
12) A person already in another clinical test when this clinical test begins.
13) A person who is presently breastfeeding, pregnant, or planning/wishing to be a pregnant during a period of this clinical test.
14) A person whom trial investigator has asessed as mismatched participant.

Target sample size

45


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Daiya Asaka

Organization

The Jikei University School of Medicine

Division name

Department of Otorhinolaryngology

Zip code


Address

3-25-8 Nishi Shinbashi, Minato-ku, Tokyo, 105-8461

TEL

03-3433-1111

Email

asaka@jikei.ac.jp


Public contact

Name of contact person

1st name
Middle name
Last name Daiya Asaka

Organization

The Jikei University School of Medicine

Division name

Department of Otorhinolaryngology

Zip code


Address

3-25-8 Nishi Shinbashi, Minato-ku, Tokyo, 105-8461

TEL

03-3433-1111

Homepage URL


Email

asaka@jikei.ac.jp


Sponsor or person

Institute

The Jikei University School of Medicine

Institute

Department

Personal name



Funding Source

Organization

The Jikei University School of Medicine

Organization

Division

Category of Funding Organization

Other

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions

東京慈恵会医科大学附属病院


Other administrative information

Date of disclosure of the study information

2018 Year 09 Month 26 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2016 Year 10 Month 18 Day

Date of IRB

2016 Year 10 Month 12 Day

Anticipated trial start date

2016 Year 11 Month 01 Day

Last follow-up date

2019 Year 03 Month 31 Day

Date of closure to data entry


Date trial data considered complete

2019 Year 03 Month 31 Day

Date analysis concluded

2019 Year 03 Month 31 Day


Other

Other related information



Management information

Registered date

2018 Year 09 Month 26 Day

Last modified on

2019 Year 04 Month 23 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000039074


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name